The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
Commentary|Articles|October 7, 2026
Etentamig, Iberdomide, and Long-Term PERSEUS Data Headline Key Myeloma Findings From IMS 2026
Author(s)Chris Ryan
Fact checked by: Riley Kandel
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Advertisement
Advertisement
Phase 3 data for the BCMA x CD3 bispecific T-cell engager etentamig, the CELMoD iberdomide (Zenbexus), long-term follow-up from the phase 3 PERSEUS trial (NCT03710603), along with early experience with in vivo CAR T-cell therapy, were among the most closely watched multiple myeloma data and trends presented at the
Related to this article
After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.
Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.
Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.
A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.
Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
Most patients treated with talquetamab at a single center would not have qualified for MonumenTAL-1, yet responses were similar regardless of trial eligibility.
Advertisement
Advertisement